Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer
International Journal of Medical Sciences · 2024
DOI: 10.7150/ijms.101855 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Medical Sciences, 2024. Verfasst von Wenjie Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, No. 123 Tianfei Street, Mocho…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Axilla, Lymph Nodes. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
This study aimed to develop a combined ultrasound (US)-pathology model to predict the axillary status more accurately after NST in breast cancer.
Methods
This retrospective study included breast cancer patients who received NST at the First Affiliated Hospital of Nanjing Medical University from 2015 to 2022. Clinical, US, and pathological data were collected. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of axillary pathological complete response (pCR). The model was developed using the predictors and validated.
Results
A total of 657 patients were enrolled in this study. Two multivariate logistic analyses were performed before and after the operation. The results showed that the clinical lymph nodes, ER status, HER2 status, chemotherapy response of primary tumor, hilum structure of axillary lymph nodes (ALNs) after NST, blood flow of ALNs after NST, vascular invasion, pathological size, and Miller-Payne grade (all p < 0.05) were independent predictors of axillary pCR. The US-based and combined US-pathology models were developed based on preoperative and postoperative information. The two models had an area under the receiver operating characteristic curve (AUC) of 0.821 and 0.883, respectively, which was significantly higher than that of the fine-needle aspiration model (AUC: 0.735).
Conclusion
In this study, based on the US-based model, a combined model incorporating the characteristics of ALNs under US and breast pathology was developed and validated to predict axillary pCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, No. 123 Tianfei Street, Mochou Road, Nanjing, 210004, China.
- Department of Breast Disease, the First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China.
- Department of Ultrasound, the First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China.
- Department of Clinical Nutrition, the First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China.
Zitieren
APA
Shi, W., He, J., Li, X., Zha, H., Chen, R., Xu, L., Zha, X., & Wang, J. (2024). Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.101855
Vancouver
Shi W, He J, Li X, Zha H, Chen R, Xu L, et al. Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer. International Journal of Medical Sciences. 2024. doi:10.7150/ijms.101855
BibTeX
@article{Shi2024,
author = {Shi, Wenjie and He, Jinzhi and Li, Xuan and Zha, Hailing and Chen, Rui and Xu, Lu and Zha, Xiaoming and Wang, Jue},
title = {Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer},
journal = {International Journal of Medical Sciences},
year = {2024},
doi = {10.7150/ijms.101855}
}
EUVIMED